STAMFORD, Conn., May 24, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that management will participate at the following investor conferences in June:
A live and archived webcast of the presentations will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.
About GeneDx
GeneDx (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by one of the world’s largest, rare disease data sets. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
Investor Relations Contact:
Tricia Truehart
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Maurissa Messier
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$129.57 |
| Daily Change: | 6.88 5.61 |
| Daily Volume: | 271,036 |
| Market Cap: | US$3.720B |
October 09, 2025 October 08, 2025 October 01, 2025 September 18, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
